Braidwell LP Acquires 2,057,460 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Braidwell LP increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 203.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,070,837 shares of the company's stock after buying an additional 2,057,460 shares during the period. Braidwell LP owned 4.49% of Replimune Group worth $33,656,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC raised its position in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Replimune Group in the first quarter worth approximately $1,088,000. Acadian Asset Management LLC lifted its stake in Replimune Group by 63.2% in the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock valued at $1,668,000 after buying an additional 71,867 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in shares of Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock worth $650,000 after buying an additional 53,313 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after buying an additional 52,498 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is currently owned by insiders.

Replimune Group Stock Up 0.2 %

Shares of REPL traded up $0.03 on Friday, reaching $14.08. The company's stock had a trading volume of 474,085 shares, compared to its average volume of 1,066,384. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The stock has a market capitalization of $963.31 million, a PE ratio of -4.62 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average of $11.89 and a 200-day moving average of $10.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities analysts predict that Replimune Group, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

REPL has been the topic of a number of research reports. Roth Mkm started coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a "buy" rating and a $17.00 target price on the stock. Roth Capital upgraded shares of Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. BMO Capital Markets increased their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $17.00.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.